Preliminary efficacy of telisotuzumab vedotin (Teliso-V) treatment in the 2L/3L setting in MET gene amplified ( MET Amp), c-Met protein overexpressing (c-Met OE), nonsquamous, non-small cell lung cancer (NSQ NSCLC): Retrospective analysis of LUMINOSITY

被引：3
|
作者：
Camidge, D. Ross
Goldman, Jonathan
Vasilopoulos, Athan
Ansell, Peter
Xia, Summer
Bolotin, Ellen
Looman, Jim
Ratajczak, Christine
Noon, Elysa
Lu, Shun
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT214
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT214
引用
收藏
页数：3
相关论文
共 37 条
  • [31] Associations of C-MET Gene Copy with EGFR Mutation and Gene Copy in EGFR-Tyrosine Kinase Inhibitor (TKI) Untreated Non-Small Cell Lung Cancer (NSCLC)
    Bae, J. M.
    Jeon, Y. K.
    Kim, Y. T.
    Seo, J. W.
    Kim, Y. A.
    Chung, D. H.
    MODERN PATHOLOGY, 2010, 23 : 397A - 397A
  • [32] Programmed death-ligand 1 (PD-L1) upregulates c-MET phosphorylation via protein tyrosine phosphatase and contributes to the development of MET amplification in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer
    Huang, Derek De-Rui
    Hsu, Chia-Chi
    Hsu, Wei-Hsun
    Liao, Bin-Chi
    Yang, James Chih-Hsin
    CANCER RESEARCH, 2024, 84 (06)
  • [33] A prospective observational study evaluating c-MET expression and EGFR gene mutation correlation with erlotinib response in second line treatment for advanced/metastatic non-small cell lung cancer patients
    Park, Cheol-Kyu
    Choi, Yoo-Duk
    Oh, In-Jae
    Lee, Jung-Eun
    Lee, Shin Yup
    Jang, Tae-Won
    Ryu, Jeong-Seon
    Kim, Young-Chul
    CANCER RESEARCH, 2017, 77
  • [34] EGFR and KRAS mutations and altered c-Met gene copy numbers in primary non-small cell lung cancer and associated stage N2 lymph node-metastasis
    Han, Cheng-Bo
    Ma, Jie-Tao
    Li, Fan
    Zhao, Jian-Zhu
    Jing, Wei
    Zhou, Yang
    Zou, Hua-Wei
    CANCER LETTERS, 2012, 314 (01) : 63 - 72
  • [35] Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)
    Cappuzzo, F.
    Moreno Garcia, V.
    Ou, S-H. I.
    Brandao, M.
    Sanmamed, M. F.
    Helissey, C.
    Wislez, M.
    Call, J. A.
    Grisanti, S.
    Johnson, M. L.
    Boni, V.
    Jamme, P.
    Monnet, I.
    Siena, S.
    Yan, C.
    Barasa, B.
    Richard, B.
    Joe, A. K.
    Laus, G.
    Felip, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S1671 - S1671
  • [36] ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase I study
    De Miguel, M.
    Yamamoto, N.
    Raimbourg, J.
    Cho, B. C.
    Gottfried, M.
    Stemmer, S. M.
    Goldman, J. W.
    Blaney, M. E.
    Jennaro, T.
    Vasilopoulos, A.
    Li, R. R.
    Freise, K. J.
    Aristide, M. R. Neagu
    Morrison-Thiele, G.
    Hunter, Z. N.
    Burns, M.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2024, 35 : S805 - S806
  • [37] Phase I/II multicenter, randomized, open-label trial of the c-Met inhibitor MSC2156119J and gefitinib versus chemotherapy as second-line treatment in patients with MET-positive (MET plus ), locally advanced, or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor mutation (EGFRm plus ) and progression on gefitinib
    Wu, Yi-Long
    Yang, James Chih-Hsin
    Park, Keunchil
    Xu, Lianzhe
    Bladt, Friedhelm
    Johne, Andreas
    Li, Peiqi
    Zheng, Hongxia
    Massimini, Giorgio
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
1234